Tuberculosis into the 2010s: Is the Glass Half Full?

    Research output: Contribution to journalArticle

    Abstract

    During the 16 years since the World Health Organization declared tuberculosis (TB) a global emergency, major new challenges have emerged-in particular the spread of extensively drug-resistant (XDR)-TB and its overlap with human immunodeficiency virus infection. However, during this period, we have also witnessed the creation of-and major commitments from-agencies dedicated to TB control, research, and funding, and tangible positive achievements have occurred; these include improvements in both new and existing TB diagnostics, a developmental pipeline of new candidate TB drugs, better treatment outcomes for multidrug-resistant TB and XDR-TB, heightened recognition of the importance of nosocomial transmission, and improved strategies to reduce mortality associated with concurrent human immunodeficiency virus infection and TB. We suggest updates to the 2006 International Standards of Tuberculosis Care to embrace these developments. The incorporation of these recent advances into optimized directly observed treatment, short course (DOTS), programs, in conjunction with more widespread deployment and enhanced political will, all provide grounds for improved control. � 2009 by the Infectious Diseases Society of America. All rights reserved.
    Original languageEnglish
    Pages (from-to)574-583
    Number of pages10
    JournalClinical Infectious Diseases
    Volume49
    Issue number4
    Publication statusPublished - 2009

    Fingerprint

    Glass
    Tuberculosis
    Virus Diseases
    Extensively Drug-Resistant Tuberculosis
    HIV
    Multidrug-Resistant Tuberculosis
    Standard of Care
    Emergencies
    Mortality
    Research
    Pharmaceutical Preparations

    Cite this

    @article{b3318427800b4c7590f9173c5adbdb4a,
    title = "Tuberculosis into the 2010s: Is the Glass Half Full?",
    abstract = "During the 16 years since the World Health Organization declared tuberculosis (TB) a global emergency, major new challenges have emerged-in particular the spread of extensively drug-resistant (XDR)-TB and its overlap with human immunodeficiency virus infection. However, during this period, we have also witnessed the creation of-and major commitments from-agencies dedicated to TB control, research, and funding, and tangible positive achievements have occurred; these include improvements in both new and existing TB diagnostics, a developmental pipeline of new candidate TB drugs, better treatment outcomes for multidrug-resistant TB and XDR-TB, heightened recognition of the importance of nosocomial transmission, and improved strategies to reduce mortality associated with concurrent human immunodeficiency virus infection and TB. We suggest updates to the 2006 International Standards of Tuberculosis Care to embrace these developments. The incorporation of these recent advances into optimized directly observed treatment, short course (DOTS), programs, in conjunction with more widespread deployment and enhanced political will, all provide grounds for improved control. � 2009 by the Infectious Diseases Society of America. All rights reserved.",
    keywords = "1 (6 bromo 2 methoxy 3 quinolinyl) 4 dimethylamino 2 (1 naphthyl) 1 phenyl 2 butanol, 2,3 dihydro 2 methyl 6 nitro 2 [4 [4 (4 trifluoromethoxyphenoxy) 1 piperidinyl]phenoxymethyl]imidazo[2,1 b]oxazole, 6,7 dihydro 2 nitro 6 (4 trifluoromethoxybenzyloxy) 5h imidazo[2,1 b][1,3]oxazine, amikacin, aminosalicylic acid, amoxicillin plus clavulanic acid, BCG vaccine, benzothiazine derivative, btz 043, capreomycin, clofazimine, cycloserine, ethambutol, ethionamide, gatifloxacin, isoniazid, kanamycin, levofloxacin, linezolid, ll 3858, moxifloxacin, n (2 adamantyl) n' geranylethylenediamine, nitroimidazole derivative, ofloxacin, protionamide, pyrazinamide, quinoline derivative, rifabutin, rifampicin, sq 609, streptomycin, terizidone, thioacetazone, tuberculostatic agent, unclassified drug, unindexed drug, bacterial transmission, comorbidity, directly observed therapy, funding, hospital infection, human, Human immunodeficiency virus infection, medical research, mortality, multidrug resistance, politics, priority journal, review, short course therapy, superinfection, treatment outcome, tuberculosis, tuberculosis control, world health organization, Communicable Disease Control, HIV Infections, Humans, Tuberculosis",
    author = "A RALPH and Nicholas Anstey and P KELLY",
    year = "2009",
    language = "English",
    volume = "49",
    pages = "574--583",
    journal = "Clinical Infectious Diseases",
    issn = "1058-4838",
    publisher = "Oxford University Press",
    number = "4",

    }

    Tuberculosis into the 2010s : Is the Glass Half Full? / RALPH, A; Anstey, Nicholas; KELLY, P.

    In: Clinical Infectious Diseases, Vol. 49, No. 4, 2009, p. 574-583.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Tuberculosis into the 2010s

    T2 - Is the Glass Half Full?

    AU - RALPH, A

    AU - Anstey, Nicholas

    AU - KELLY, P

    PY - 2009

    Y1 - 2009

    N2 - During the 16 years since the World Health Organization declared tuberculosis (TB) a global emergency, major new challenges have emerged-in particular the spread of extensively drug-resistant (XDR)-TB and its overlap with human immunodeficiency virus infection. However, during this period, we have also witnessed the creation of-and major commitments from-agencies dedicated to TB control, research, and funding, and tangible positive achievements have occurred; these include improvements in both new and existing TB diagnostics, a developmental pipeline of new candidate TB drugs, better treatment outcomes for multidrug-resistant TB and XDR-TB, heightened recognition of the importance of nosocomial transmission, and improved strategies to reduce mortality associated with concurrent human immunodeficiency virus infection and TB. We suggest updates to the 2006 International Standards of Tuberculosis Care to embrace these developments. The incorporation of these recent advances into optimized directly observed treatment, short course (DOTS), programs, in conjunction with more widespread deployment and enhanced political will, all provide grounds for improved control. � 2009 by the Infectious Diseases Society of America. All rights reserved.

    AB - During the 16 years since the World Health Organization declared tuberculosis (TB) a global emergency, major new challenges have emerged-in particular the spread of extensively drug-resistant (XDR)-TB and its overlap with human immunodeficiency virus infection. However, during this period, we have also witnessed the creation of-and major commitments from-agencies dedicated to TB control, research, and funding, and tangible positive achievements have occurred; these include improvements in both new and existing TB diagnostics, a developmental pipeline of new candidate TB drugs, better treatment outcomes for multidrug-resistant TB and XDR-TB, heightened recognition of the importance of nosocomial transmission, and improved strategies to reduce mortality associated with concurrent human immunodeficiency virus infection and TB. We suggest updates to the 2006 International Standards of Tuberculosis Care to embrace these developments. The incorporation of these recent advances into optimized directly observed treatment, short course (DOTS), programs, in conjunction with more widespread deployment and enhanced political will, all provide grounds for improved control. � 2009 by the Infectious Diseases Society of America. All rights reserved.

    KW - 1 (6 bromo 2 methoxy 3 quinolinyl) 4 dimethylamino 2 (1 naphthyl) 1 phenyl 2 butanol

    KW - 2,3 dihydro 2 methyl 6 nitro 2 [4 [4 (4 trifluoromethoxyphenoxy) 1 piperidinyl]phenoxymethyl]imidazo[2,1 b]oxazole

    KW - 6,7 dihydro 2 nitro 6 (4 trifluoromethoxybenzyloxy) 5h imidazo[2,1 b][1,3]oxazine

    KW - amikacin

    KW - aminosalicylic acid

    KW - amoxicillin plus clavulanic acid

    KW - BCG vaccine

    KW - benzothiazine derivative

    KW - btz 043

    KW - capreomycin

    KW - clofazimine

    KW - cycloserine

    KW - ethambutol

    KW - ethionamide

    KW - gatifloxacin

    KW - isoniazid

    KW - kanamycin

    KW - levofloxacin

    KW - linezolid

    KW - ll 3858

    KW - moxifloxacin

    KW - n (2 adamantyl) n' geranylethylenediamine

    KW - nitroimidazole derivative

    KW - ofloxacin

    KW - protionamide

    KW - pyrazinamide

    KW - quinoline derivative

    KW - rifabutin

    KW - rifampicin

    KW - sq 609

    KW - streptomycin

    KW - terizidone

    KW - thioacetazone

    KW - tuberculostatic agent

    KW - unclassified drug

    KW - unindexed drug

    KW - bacterial transmission

    KW - comorbidity

    KW - directly observed therapy

    KW - funding

    KW - hospital infection

    KW - human

    KW - Human immunodeficiency virus infection

    KW - medical research

    KW - mortality

    KW - multidrug resistance

    KW - politics

    KW - priority journal

    KW - review

    KW - short course therapy

    KW - superinfection

    KW - treatment outcome

    KW - tuberculosis

    KW - tuberculosis control

    KW - world health organization

    KW - Communicable Disease Control

    KW - HIV Infections

    KW - Humans

    KW - Tuberculosis

    UR - http://www.scopus.com/inward/record.url?scp=67651089506&partnerID=8YFLogxK

    M3 - Article

    VL - 49

    SP - 574

    EP - 583

    JO - Clinical Infectious Diseases

    JF - Clinical Infectious Diseases

    SN - 1058-4838

    IS - 4

    ER -